首页|Ki-67在乳腺癌及腋窝转移淋巴结中的表达及临床应用

Ki-67在乳腺癌及腋窝转移淋巴结中的表达及临床应用

The clinical application of Ki-67 expression in breast cancer and metastatic lymph nodes

扫码查看
目的 探讨免疫细胞化学逆染Ki-67蛋白在乳腺癌及转移淋巴结细胞中的表达及临床应用.方法 选取潍坊市中医院2021年12月~2023年6月经影像学评估腋窝可疑转移的61例乳腺癌患者,行超声引导下乳腺肿物细针穿刺活检+原发肿物粗针穿刺活检+影像学评估可疑淋巴结的细针穿刺活检术;评估细针穿刺同粗针穿刺的差异;对穿刺腋窝淋巴结证实转移后45例患者行免疫细胞化学逆染Ki-67染色,进行二次分析.结果 61例患者乳腺癌细针穿刺与粗针穿刺比较,诊断乳腺癌准确性同为100%,但对病理类型的分型略有差别.45例证实转移的患者中,Ki-67在转移淋巴结和原发灶的变异率为11.1%.当把转移灶/原发灶Ki-67比值作为研究对象时,患者乳腺癌原发分型和新辅助化疗后病理完全缓解(pCR)率之间存在统计学差异(P<0.05),年龄、乳腺癌原发灶人表皮生长因子受体2(HER-2)、分期、雌激素受体(ER)和孕激素受体(PR)比较,统计学无差异(P>0.05);行新辅助化疗后pCR单因素分析,乳腺Ki-67[95%置信区间(0.912-0.996)]及腋窝/原发灶Ki-67比值[95%置信区间(7.651-677.567)]具有相关性(P<0.05),在单因素分析中,满足P<0.1的变量被纳入多因素Logistic回归分析.结果显示,仅乳腺癌转移腋窝淋巴结/原发灶的Ki-67比值[53.698(5.425-531.538)]与患者新辅助化疗后的pCR相关(P<0.05),而乳腺原发灶的Ki-67[0.976(0.920-1.035)]与此无显著相关性(P>0.05).结论 乳腺癌转移腋窝淋巴结/原发灶分子Ki-67表达可能预测新辅助化疗后的pCR.
Objective To investigate the difference and correlation between the expression of Ki-67 protein in metastatic lymph nodes and the primary breast tumor cells by immunocytochemistry reverse staining.Methods Sixty-one breast cancer patients with suspected axillary metastasis were collected from Weifang Hospital of Traditional Chinese Medicine.Ultrasound-guided fine-needle aspiration biopsy of the breast mass,coarse-needle aspiration biopsy of the pri-mary tumor and fine needle aspiration biopsy of suspected metastatic lymph nodes of imaging assessed were performed on these patients;then to evaluate the difference during these methods.The secondary analysis was performed in 45 patients with axillary lymph node metastasis confirmed via immunocytochemistry Ki-67 reverse staining.Results In 61 patients with breast cancer,the accuracy of fine-needle aspiration biopsy and coarse-needle aspiration biopsy was both 100%,but there was a slight difference in the classification of pathological types.In 45 patients with metastasis,the variation rate of Ki-67 in metastatic lymph nodes and primary lesions was 11.1%.When armpit/primary Ki-67 ratio was performed,there were statistical differences in the primary classification and pathological complete response(PCR)after neoadjuvant chemotherapy in breast cancer(P<0.05),while there were no statistically significant differences in age,stage,estrogen receptor(ER),progestogen receptor(PR),and human epidermal growth factor receptor 2(HER-2)in primary breast cancer(P>0.05).In the single-factor analysis of PCR after neoadjuvant chemotherapy,a significant correlation was wit-nessed between the Ki-67 of breast cancer[0.912 and 0.996(95%confidence interval)]and the Ki-67 ratio of axilla-ry/primary[7.651 and 677.567(95%confidence interval)](P<0.05).In univariate analysis,variables with P<0.1 were included in the multivariate logistic regression analysis.The results indicated that only the Ki-67 ratio[53.698(5.425-531.538)]of axillary lymph node/primary focus of breast cancer metastasis was related to the pCR after neoadju-vant chemotherapy(P<0.05),while the Ki-67 ratio[0.976(0.920-1.035)]of primary focus of breast cancer was not significantly related to pCR after neoadjuvant chemotherapy(P>0.05).Conclusion The expression of Ki-67 in breast cancer metastatic axillary lymph nodes/primary breast cancer may predict PCR after neoadjuvant chemotherapy.

Breast cancerAxilla metastatic lymph nodeFine-needle aspiration biopsyImmunocytochemis-tryKi-67

宋以宁、史明明、陈文信、邵光东、金占杰、李璟、李国楼、王晓琳

展开 >

潍坊市中医院乳腺甲状腺外科,山东潍坊 261041

潍坊市中医院教学培训部

潍坊市中医院病理科

乳腺癌 转移淋巴结 细针吸取 免疫细胞化学 Ki-67

2024

潍坊医学院学报
潍坊医学院

潍坊医学院学报

影响因子:0.185
ISSN:1004-3101
年,卷(期):2024.46(6)